Cortexin vs P21.

Cortexin is a low-molecular-weight polypeptide preparation extracted from the cerebral cortex of cattle and calves. It contains a mixture of short water-soluble peptides (roughly 1 to 10 kDa), amino acids and trace elements, and is supplied as a lyophilized powder reconstituted for intramuscular injection. Developed and marketed primarily in Russia by GEROPHARM, it is positioned as a neurotrophic and neuroprotective agent. It is used clinically within Russia and several neighboring countries for a range of neurological conditions.

P21 (also written P021) is a small synthetic peptide derivative modeled on a biologically active region of ciliary neurotrophic factor (CNTF). It was designed by researchers at the New York State Institute for Basic Research to be an orally active, blood-brain-barrier-penetrant neurotrophic compound. It has been investigated in animal models of Alzheimer's disease, Down syndrome and other neurodegenerative and neurodevelopmental conditions. It is an early-stage research compound that has not been tested in humans.

Like other brain-tissue peptide preparations, Cortexin is a complex mixture, so its activity is attributed to the combined effect of many peptide-protein interactions rather than a single molecular target. Proposed mechanisms include support of neuronal energy metabolism, antioxidant and anti-apoptotic effects, and modulation of neurotrophic factors and neurotransmitter systems such as GABA and dopamine. Its low-molecular-weight peptides are claimed to cross the blood-brain barrier. These mechanisms are largely inferred from preclinical models.

P21 is reported to act partly by inhibiting the leukemia inhibitory factor (LIF) signaling pathway and by increasing transcription of brain-derived neurotrophic factor (BDNF). Elevated BDNF is proposed to enhance neurogenesis and synaptic plasticity and to reduce the activity of GSK-3 beta, an enzyme that drives abnormal tau phosphorylation. Through this pathway it is hypothesized to have a disease-modifying effect on tau-related pathology. These mechanisms are drawn from cell-culture and rodent studies.

The evidence base for Cortexin comes predominantly from Russian-language studies and preclinical models, with limited independent Western validation. A recent preclinical study (Kurkin et al., Biomedicines 2025) reported neurotropic effects in rat models of toxic and traumatic developmental delay. Clinical use is widespread in Russia across pediatric neurology, stroke rehabilitation and cognitive disorders, but large, blinded, international randomized trials indexed in mainstream databases are scarce. As a result, Cortexin has not been subjected to the RCT and Cochrane-level scrutiny applied to Cerebrolysin. Its efficacy claims should therefore be read with caution. The human literature is dominated by multicenter observational programs rather than randomized comparisons: the CORNELia program in chronic cerebrovascular disease with cognitive impairment and the CORTEX program in post-COVID neurological complaints are both described as observational, meaning they lack a concurrent randomized control arm, blinding, and placebo control, so improvement over time cannot be separated from natural recovery, regression to the mean or expectation effects. Comparative studies do exist within the same national literature, for example a comparison with another peptide preparation in the early recovery period after ischaemic stroke, but these are typically single-country, modest in size and published in one journal, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, closely associated with the domestic market for the drug. Preclinical support includes rodent work on antioxidant effects in chronic cerebrovascular insufficiency and a cell-culture study reporting protection of cultured rat sensory neurons from high-glucose injury. Nearly all of this literature originates in the country where the product is registered and marketed, and the manufacturer's involvement in the observational programs is a relevant consideration. What is missing is specific: no independent multinational randomized trial, no Cochrane or comparable systematic review, no published characterization of which peptides in the extract are active, and no external regulatory assessment of the manufacturing and potency standards. Cortexin sits alongside thymalin, vilon and epitalon in resting on single-country literature, while Cerebrolysin, despite its own unresolved questions, has at least been tested in independently reviewed randomized trials.

The evidence for P21 is entirely preclinical and comes largely from a single research group. In triple-transgenic Alzheimer's (3xTg-AD) mice, chronic oral P021 reduced tau hyperphosphorylation and rescued neurogenesis, synaptic markers and cognition (Kazim et al., Neurobiology of Disease 2014). A later study reported that early P021 treatment prevented dendritic and synaptic deficits and cognitive impairment in the same model (Baazaoui and Iqbal, Alzheimer's Research and Therapy 2017). Subsequent work from the same laboratory extended the approach to treatment begun in early postnatal development, again in a transgenic rodent model, and reported prevention of Alzheimer-like behavior and synaptic dysfunction (Journal of Alzheimer's Disease, 2021). A later review by the same investigators frames the compound as a therapeutic opportunity to be tested rather than an established treatment (Biomolecules, 2022). The design of this body of work sets clear limits on what it can support. These are rodent experiments in genetically engineered models that reproduce selected features of human Alzheimer's pathology and that have a long record of poor translation to the clinic. They were conducted by the originating institution rather than by independent replicating laboratories, and the published reports are academic studies, not blinded, multi-site, pre-registered confirmatory trials. The outcomes are surrogate measures: phosphorylated tau, synaptic protein density, neurogenesis markers, and rodent behavioral tasks. None is a clinical endpoint, and treatment durations span weeks to months of animal life rather than years of human disease. What is unknown is more substantial than what has been shown. No human clinical trial of P21 has been completed or registered. There is therefore no Phase 1 dataset, no human pharmacokinetic or bioavailability profile despite the oral-activity claim, no characterized exposure range, and no published formal toxicology package. The contrast with the class it is compared against is stark: approved central nervous system drugs for Alzheimer's disease have moved through sequential Phase 1, 2 and 3 programs enrolling thousands of participants with adjudicated cognitive and functional endpoints, and even candidates that failed later usually established a human tolerability and exposure baseline in Phase 1. P21 has not reached that first step. Positive rodent findings do not establish efficacy or safety in people.

Cortexin is generally described in its clinical literature as well tolerated when given intramuscularly, with hypersensitivity and allergic reactions being the main labeled concern. As a parenteral bovine-derived biological, theoretical risks include allergic reactions and injection-site effects, and the same category concerns apply that attach to any animal-tissue extract given by injection: immunogenicity on repeated courses, dependence on the source herd and purification process for freedom from adventitious agents, and the practical difficulty of proving batch equivalence for a mixture whose active constituents are not defined. Independent long-term safety data from outside its region of use are limited, and the observational design of most human reports means adverse events were collected without a comparator, so background rates cannot be separated from drug-related events. Use in children, which is common in the Russian pediatric neurology setting, has not been evaluated in independently reviewed controlled trials, and pediatric exposure is precisely the situation where an external safety assessment would ordinarily be required. Product acquired outside licensed pharmacy channels carries additional contamination and counterfeit risk, since injectables demand verified sterility and endotoxin control that unregulated supply cannot demonstrate. A trial-grade safety evaluation would include prospective adverse-event capture against a control arm, hypersensitivity monitoring, hepatic and renal laboratory follow-up, and anti-drug antibody testing on repeat courses. It is a prescription clinical product, not a dietary supplement.

There are no human safety data for P21; all safety information comes from short- to medium-term rodent studies, where it was reported to be tolerated. Long-term effects, appropriate exposure and human toxicology are unknown. No published Phase 1 study has characterized adverse events, dose-limiting toxicity, immunogenicity, or interactions with other medicines in people, and there is no public repeat-dose toxicology, reproductive toxicity, or carcinogenicity dataset of the kind regulators expect before first-in-human testing. Because the proposed mechanism involves raising brain-derived neurotrophic factor and modulating leukemia inhibitory factor signaling, pathways that influence cell growth, survival and inflammation in many tissues, chronic systemic effects cannot be excluded on the basis of rodent behavioral studies alone. Material sold as a research chemical is not quality-controlled for purity or identity. Products of this type are produced outside pharmaceutical good manufacturing practice oversight, are not reliably tested batch by batch for peptide content, related-substance impurities, endotoxin, or residual synthesis reagents, and are labeled for laboratory use rather than administration. A purchaser has no practical way to verify what a vial contains, and the sterility of any reconstituted preparation is unverified. The absence of documented adverse events should not be read as evidence of safety. It reflects the absence of any human exposure under systematic observation, not a record of uneventful use: with no clinical monitoring, no adverse-event reporting channel and no registry, harms would simply go unrecorded. It is not a medicine and is not intended for human use.

Cortexin is not FDA-approved and is not marketed in the United States or the European Union. It is a registered prescription medicine in Russia and several post-Soviet states. This summary is educational and includes no dosing information.

P21 is not approved by the FDA or any other regulatory authority and has no approved medical use. It exists only as a preclinical research compound. This content is educational only and contains no dosing guidance.